logo-loader

Hemispherx BioPharma reports positive results on ovarian cancer treatment

Published: 22:40 01 May 2019 AEST

Hemispherx BioPharma (NYSE American:HEB) CEO Thomas Equels tells Proactive Investors that the biopharma has made significant progress in the study of its flagship drug Ampligen in treating ovarian cancer.

Equels is presenting at the Planet MicroCap Showcase today, in Las Vegas. A live webcast of the presentation can be viewed here:

https://www.webcaster4.com/Webcast/Page/2059/30408

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

12 hours, 37 minutes ago